OXFORD, United Kingdom, Feb. 09, 2018 (GLOBE NEWSWIRE) — Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for rare diseases and infectious diseases, announces that management will participate in two upcoming investor conferences in New York City, US.
- BIO CEO & Investor Conference – 12 February 2018, presentation at 3:15pm EST
- SunTrust Robinson Humphrey 4th Annual Orphan Drug Day – 13 February 2018
A live audio webcast of the BIO CEO presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. For the SunTrust Robinson Humphrey Orphan Drug Day, the Company will participate in one on one meetings.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
|Glyn Edwards / Richard Pye (UK office)||Tel:||44 (0)1235 443 951|
|Erik Ostrowski / Michelle Avery (US office)||+1 617 225 4455|
|Cairn Financial Advisers LLP (Nominated Adviser)||Tel:||+44 (0)20 7213 0880|
|Liam Murray / Tony Rawlinson|
|N+1 Singer (Joint Broker)||Tel:||+44 (0)20 7496 3000|
|Aubrey Powell / Jen Boorer|
|Panmure Gordon (Joint Broker)||Tel:||+44 (0)20 7886 2500|
|Freddy Crossley / Duncan Monteith, Corporate Finance|
|Tom Salvesen, Corporate Broking|
|MacDougall Biomedical Communications (US)||Tel:||+1 781 235 3060|
|Consilium Strategic Communications (UK)||Tel:||+44 (0)20 3709 5700|
|Mary-Jane Elliott / Sue Stuart /||email@example.com|
|Jessica Hodgson / Philippa Gardner|